
share. Including the recently acquired LabOne business, Quest's second-quarter revenue grew by 15%. LabOne contributed approximately 10% of the ..... Quest's kit-manufacturing unit and LabOne integration costs. Bad debt expense dipped
now, but we'll consider raising our estimate as we review the financials. Total sales grew by roughly 18%, including the LabOne acquisition. More importantly, organic sales grew nearly 8%--a strong showing. Clinical testing volume grew 9%, with
announcement that Quest Diagnostics DGX plans to acquire LabOne LABS makes strategic sense and offers a nice 25% premium to our LabOne fair value estimate of $31 per share. The addition of LabOne does not necessarily change the big picture for Quest
LabOne 's LABS first-quarter results surpassed ..... While we expected strong revenue growth, LabOne exceeded our gross margin forecast. Increased ..... the prior-year period. We anticipate LabOne will continue to improve margins as it augments